Cost Insights: Breaking Down Exelixis, Inc. and Perrigo Company plc's Expenses

Explore Exelixis and Perrigo's expense trends over a decade.

__timestampExelixis, Inc.Perrigo Company plc
Wednesday, January 1, 201420430002613100000
Thursday, January 1, 201538950002891500000
Friday, January 1, 201665520003228800000
Sunday, January 1, 2017150660002966700000
Monday, January 1, 2018263480002900200000
Tuesday, January 1, 2019330970003064100000
Wednesday, January 1, 2020362720003248100000
Friday, January 1, 2021528730002722500000
Saturday, January 1, 2022579090002996200000
Sunday, January 1, 2023725470002975200000
Monday, January 1, 20240
Loading chart...

In pursuit of knowledge

Cost Insights: A Comparative Analysis of Exelixis, Inc. and Perrigo Company plc's Expenses

In the ever-evolving landscape of the pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Exelixis, Inc. and Perrigo Company plc from 2014 to 2023. Over this period, Exelixis, Inc. has seen a staggering increase in its cost of revenue, growing by over 3,400%, from approximately $2 million in 2014 to $72 million in 2023. This reflects the company's aggressive expansion and investment in research and development. In contrast, Perrigo Company plc's cost of revenue has remained relatively stable, fluctuating around the $3 billion mark, indicating a consistent operational strategy. This stability suggests a mature market presence and efficient cost management. As the pharmaceutical sector continues to innovate, these insights provide a window into the financial strategies of two key players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025